Coya Therapeutics Receives $5 Million Investment from the Alzheimer’s Drug Discovery Foundation
Investment from the Alzheimer’s Drug Discovery Foundation (ADDF) aims to support the development of Coya 302, a therapeutic candidate for the treatment of frontotemporal dementia (FTD).
